Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13911904 | 1.00 | CYP2C9 (0.38) | CYP2C9HTTLMNAALDH1A1TSHR | |
| SCHEMBL11901721 | 1.00 | CYP2C9 (0.38) | CYP2C9HTTLMNAALDH1A1TSHR | |
| SCHEMBL2572352 | 0.77 | ALDH1A1 (0.38) | CYP2C9HTTLMNAALDH1A1TSHR | |
| SCHEMBL2572768 | 0.76 | CA12 (0.37) | CYP2C9HTTLMNAALDH1A1TSHR | |
| SCHEMBL12682934 | 0.76 | CA12 (0.38) | CYP2C9LMNAALDH1A1GAAMGAM | |
| SCHEMBL16487170 | 0.74 | MGAM (0.37) | CYP2C9LMNAALDH1A1GAAMGAM | |
| SCHEMBL837941 | 0.72 | MGAM (0.42) | CYP2C9LMNAALDH1A1GAAMGAM | |
| SCHEMBL8562716 | 0.71 | SMN1; SMN2 (0.48) | CYP2C9ALDH1A1TSHRGAAMGAM | |
| SCHEMBL2566491 | 0.71 | ALDH1A1 (0.33) | CYP2C9ALDH1A1TSHRGAAL3MBTL1 | |
| SCHEMBL16532654 | 0.70 | ALDH1A1 (0.37) | CYP2C9HTTLMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230192702-A1 | PROCESS FOR THE PREPARATION OF VERDIPERSTAT | BIOHAVEN THERAPEUTICS LTD (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| EP-3386591-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3386591-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3386591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | CYP2C9 887/4885HTT 4398/4885LMNA 1066/4885 |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | CYP2C9 2214/4885HTT 542/4885LMNA 4824/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | CYP2C9 2214/4885HTT 542/4885LMNA 4824/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | CYP2C9 554/4885HTT 2258/4885LMNA 2478/4885 |
| US-20230192702-A1 | PROCESS FOR THE PREPARATION OF VERDIPERSTAT | GNPAT, DDT, AASDHPPT | CYP2C9 261/4885HTT 553/4885LMNA 2376/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | CYP2C9 2214/4885HTT 542/4885LMNA 4824/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | CYP2C9 2214/4885HTT 542/4885LMNA 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.